Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976047 | 0.89 | DAO (0.60) | DAOMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL9976088 | 0.81 | DAO (0.59) | DAOMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL9010390 | 0.79 | DAO (0.68) | DAOMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL30150593 | 0.78 | RAB9A (0.62) | MEN1KMT2ARAB9AMAPK1MAPT | |
| SCHEMBL1323646 | 0.78 | RAB9A (0.62) | MEN1KMT2ARAB9AMAPK1MAPT | |
| Bromide SCHEMBL27462942 | 0.76 | RAB9A (0.60) | MEN1KMT2ARAB9AMAPK1MAPT | |
| SCHEMBL1584925 | 0.76 | RAB9A (0.56) | DAOMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL2116925 | 0.76 | RAB9A (0.75) | DAOMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL11863320 | 0.76 | LOXL2 (0.57) | DAOMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL2116138 | 0.76 | KMT2A (0.59) | DAOMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | MECP2, DNMT1, DNMT3B | DAO 2704/4885MEN1 3018/4885KMT2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.